We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y
Read MoreHide Full Article
Aerie Pharmaceuticals Inc. reported a loss of 65 cents per share in third-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of 81 cents. The loss in the year-ago quarter was 86 cents per share.
Revenues came in at $20.1 million, which increased from $18.5 million in the year-ago quarter and beat the Zacks Consensus Estimate of $19 million.
Shares of the company have slumped 55.6% year to date compared with the industry’s decline of 3.7%.
Total revenues came from sales of two approved drugs —Rhopressa and Rocklatan.
The company’s first drug, Rhopressa (netarsudil ophthalmic solution), has been approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Aerie’s second drug, Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Pfizer’s (PFE - Free Report) Xalatan, has been approved to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Quarter in Detail
Wholesaler shipments totaled 261,000 bottles,more than 12% higher than 232,500 bottles in the second quarter of 2020.
Total operating expenses (excluding stock-based compensation expenses) in the quarter were $39 million, down from the year-ago quarter’s $49.2 million.
Pipeline Update
Aerie and Santen entered into an exclusive license agreement for the development and commercialization of Rhopressa and Rocklatan in Japan and several other Asian countries. The agreement includes an upfront payment of $50 million to Aerie. Aerie expects to initiate the first phase III study in Japan for Rhopressa® by the end of 2020.
The company expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use on the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% (marketed as Rocklatanin the United States) in the fourth quarter of 2020.
Aerie reported positive top-line data from the Rocklatan Mercury 3 phase III study in Europe in September 2020. Rocklatan (known as Roclanda in Europe) achieved non-inferiority to a fixed-dose combination in Europe (Ganfort) and received early interest from potential collaborators.
Aclaris’ loss per share estimates have narrowed from $1.43 to $1.26 for 2020 and from $1.38 to $1.10 for 2021 in the past 90 days. Shares of the company have increased 110.1% year to date.
BioLineRx’sloss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have decreased 25.7% year to date.
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y
Aerie Pharmaceuticals Inc. reported a loss of 65 cents per share in third-quarter 2020, narrower than the Zacks Consensus Estimate of a loss of 81 cents. The loss in the year-ago quarter was 86 cents per share.
Revenues came in at $20.1 million, which increased from $18.5 million in the year-ago quarter and beat the Zacks Consensus Estimate of $19 million.
Shares of the company have slumped 55.6% year to date compared with the industry’s decline of 3.7%.
Total revenues came from sales of two approved drugs —Rhopressa and Rocklatan.
The company’s first drug, Rhopressa (netarsudil ophthalmic solution), has been approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Aerie’s second drug, Rocklatan, a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Pfizer’s (PFE - Free Report) Xalatan, has been approved to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Quarter in Detail
Wholesaler shipments totaled 261,000 bottles,more than 12% higher than 232,500 bottles in the second quarter of 2020.
Total operating expenses (excluding stock-based compensation expenses) in the quarter were $39 million, down from the year-ago quarter’s $49.2 million.
Pipeline Update
Aerie and Santen entered into an exclusive license agreement for the development and commercialization of Rhopressa and Rocklatan in Japan and several other Asian countries. The agreement includes an upfront payment of $50 million to Aerie. Aerie expects to initiate the first phase III study in Japan for Rhopressa® by the end of 2020.
The company expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use on the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% (marketed as Rocklatanin the United States) in the fourth quarter of 2020.
Aerie reported positive top-line data from the Rocklatan Mercury 3 phase III study in Europe in September 2020. Rocklatan (known as Roclanda in Europe) achieved non-inferiority to a fixed-dose combination in Europe (Ganfort) and received early interest from potential collaborators.
Zacks Rank & Stocks to Consider
Aerie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Aclaris Therapeutics Inc. (ACRS - Free Report) and BioLineRx Ltd,. Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aclaris’ loss per share estimates have narrowed from $1.43 to $1.26 for 2020 and from $1.38 to $1.10 for 2021 in the past 90 days. Shares of the company have increased 110.1% year to date.
BioLineRx’sloss per share estimates have narrowed from $1.95 to $1.67 for 2020 and from $1.44 to $1.36 for 2021 in the past 60 days. Shares of the company have decreased 25.7% year to date.
Aerie Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Aerie Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Aerie Pharmaceuticals, Inc. Quote
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>